4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow MK-0524: new trials by email Literature Review of MK-0524 trials Research Report on MK-0524
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032) niacin (+) laropiprant, Comparator: placebo (unspecified) - Dyslipidemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 575 | 2005-06-01 | 2017-02-17 |
| MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED) Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks, Comparator : niacin / Duraton of Treatment: 4 Weeks - Hypercholesterolemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 407 | 2005-04-01 | 2017-04-07 |
| MK0524A Phase IIb Study (0524A-011)(COMPLETED) Comparator: niacin / Duration of Treatment: 17 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks - Flushing | Phase 2 | Completed | Merck Sharp & Dohme LLC | 154 | 2004-08-01 | 2015-08-25 |
| MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED) MK0524 - Seasonal Allergies | Phase 2 | Completed | Merck Sharp & Dohme LLC | 766 | 2003-07-01 | 2015-12-22 |
Dyslipidemias (1) · Flushing (1) · Hypercholesterolemia (1) · Rhinitis, Allergic, Seasonal (1)